THERAFLU NIGHTTIME SEVERE COLD & COUGH OTC
Generic Name and Formulations:
Acetaminophen 325mg, chlorpheniramine maleate 2mg, dextromethorphan HBr 10mg, phenylephrine HCl 5mg; caplets.
Novartis Consumer Health
Indications for THERAFLU NIGHTTIME SEVERE COLD & COUGH:
Nasal and sinus congestion, rhinorrhea, cough, sore throat, fever, headache, minor aches and pains.
2 caplets every 4 hours; max 12 caplets/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Glaucoma. Asthma. Lower respiratory disorders. Discontinue if symptoms worsen or persist after 2–7 days. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers may increase the pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + antitussive + sympathomimetic.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children, hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation